Hypothesis

Intestinal AMPK activation releases extracellular vesicles packed with specific microRNAs and succinate that travel via vagal afferents to the hypothalamus, where they reprogram microglial metabolism and suppress neuroinflammatory mTORC1 signaling, thereby extending lifespan.

Mechanistic Model

1. AMPK‑dependent vesicle biogenesis – Energy stress in enterocytes activates AMPK, which phosphorylates Rab27a at S72, enhancing multivesicular body docking and exosome release (based on AMPK regulation of Rab GTPases in 2).
2. Cargo loading – AMPK stimulates the miRNA‑processing enzyme Dicer via direct phosphorylation, enriching vesicles with miR‑34a‑5p and miR‑29c‑3p; concurrently, AMPK‑driven TCA cycle flux raises intracellular succinate, which is packaged into vesicles through the SLC25A10 carrier.
3. Vagal transmission – Vesicles bind to nodose ganglion receptors expressing integrin αvβ5, triggering vagal afferent firing that conveys the signal to the nucleus tractus solitarius and then to the hypothalamus.
4. Hypothalamic action – Vesicular miRNAs inhibit hypothalamic PTEN, augmenting AKT‑mediated FOXO1 nuclear exclusion, while succinate stabilizes HIF‑1α in microglia, shifting them toward a reparative phenotype and reducing mTORC1 activity via Sestrin2 induction.
5. Outcome – Reduced microglial mTORC1 lowers IL‑1β production, preserves synaptic integrity, and promotes systemic autophagy, mirroring the brain‑wide effects seen with gut‑specific AMPK activation in Drosophila 1.

Testable Predictions

• Prediction 1: Genetic inhibition of Rab27a in intestinal epithelial cells will block vesicle release, abolish hypothalamic miR‑34a‑5p elevation, and shorten lifespan despite gut‑specific AMPK activation.
• Prediction 2: Pharmacological vagotomy or chemogenetic silencing of nodose ganglia will prevent vesicle‑induced microglial HIF‑1α stabilization and fail to extend lifespan.
• Prediction 3: Succinate‑loaded vesicles administered intranasally to aged mice will recapitulate the longevity benefits of gut AMPK activation, an effect lost when vesicles are depleted of succinate via SLC25A10 knock‑down.
• Prediction 4: Inhibiting Dicer in enterocytes will reduce vesicular miRNA content, attenuate FOXO1 modulation in the hypothalamus, and diminish autophagy markers in brain tissue.

Experimental Design

• Use Villin‑CreERT2;Rab27a^fl/fl mice for inducible intestinal Rab27a knockout; treat with gut‑specific AMPK activator (e.g., AICAR conjugated to an enterocyte‑targeting peptide). Measure vesicle concentration in plasma, miRNA levels in hypothalamic lysates, microglial p‑S6K (mTORC1 readout), and survival.
• Apply chemogenetic hM4Di DREADDs to nodose ganglion neurons (Phox2b‑Cre) and administer CNO during AMPK activation.
• Isolate intestinal exosomes, manipulate succinate loading via Villin‑CreERT2;SLC25A10^fl/fl, and administer via retrograde vagal infusion or intranasal route.
• Include controls: scrambled vesicles, vehicle, and systemic AMPK activation to confirm gut specificity.

Potential Pitfalls and Alternatives

• Vesicle heterogeneity may confound cargo attribution; use density gradient gradients and proteomics to isolate exosome subpopulations.
• Compensatory hepatic AMPK activation could contribute; include liver‑specific AMPK knockout to isolate intestinal effect.
• If vagal signaling is not required, consider humoral circulation via the portal vein as an alternative route; test with portal vein ligation.

This framework repositions the gut as a metabolic sensor that programs central aging pathways through defined vesicular metabolites, offering a clear, falsifiable route to engineer bottom‑up longevity interventions.